Utility of the serum CRP value for assessing the prognosis and therapeutic response of urological malignancies;Stellenwert des Serum-CRP-Wertes zur Einschätzung von Prognose und therapeutischem Ansprechen urologischer Malignome

Aktuelle Urologie

Volumn 44, Issue 6, 2013, Pages 452-455

  Kohler A ^a   Eggers, H ^a   Kuczyk, M A ^a   Schrader, A J ^b   Steffens, S ^a  

^a HANNOVER MEDICAL SCHOOL   (Germany)

^b UNIVERSITY HOSPITAL ULM   (Germany)

Author keywords

bladder cancer; c reactive protein; prognostic marker; prostate cancer kidney cancer; urological cancer

Indexed keywords

C REACTIVE PROTEIN; TUMOR MARKER;

BLOOD; CARCINOMA, RENAL CELL; CARCINOMA, TRANSITIONAL CELL; DISEASE COURSE; DISEASE FREE SURVIVAL; FEMALE; HUMAN; KIDNEY NEOPLASMS; MALE; METABOLISM; MORTALITY; PENILE NEOPLASMS; PROGNOSIS; PROSTATIC NEOPLASMS; PROSTATIC NEOPLASMS, CASTRATION-RESISTANT; URINARY BLADDER NEOPLASMS;

BIOMARKERS, TUMOR; C-REACTIVE PROTEIN; CARCINOMA, RENAL CELL; CARCINOMA, TRANSITIONAL CELL; DISEASE PROGRESSION; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; KIDNEY NEOPLASMS; MALE; PENILE NEOPLASMS; PROGNOSIS; PROSTATIC NEOPLASMS; PROSTATIC NEOPLASMS, CASTRATION-RESISTANT; URINARY BLADDER NEOPLASMS;

EID: 84888385333     PISSN: 00017868     EISSN: 14388820     Source Type: Journal    
DOI: 10.1055/s-0033-1358677     Document Type: Article

References (44)

1. Jabs W. J., Busse M., Kruger S. et al. Expression of C-reactive protein by renal cell carcinomas and unaffected surrounding renal tissue. Kidney international: 2005; 68 2103 2110 (Pubitemid 43117784)
2. Stark J. R., Li H., Kraft P. et al. Circulating prediagnostic interleukin-6 and C-reactive protein and prostate cancer incidence and mortality. International journal of cancer: 2009; 124 2683 2689
3. Karakiewicz P. I., Hutterer G. C., Trinh Q. D. et al. C-reactive protein is an informative predictor of renal cell carcinoma-specific mortality: a European study of 313 patients. Cancer: 2007; 110 1241 1247 (Pubitemid 47435594)
4. Mahmoud F. A., Rivera N. I. The role of C-reactive protein as a prognostic indicator in advanced cancer. Current oncology reports: 2002; 4 250 255
5. Weinstein P. S., Skinner M., Sipe J. D. et al. Acute-phase proteins or tumour markers: the role of SAA, SAP, CRP and CEA as indicators of metastasis in a broad spectrum of neoplastic diseases. Scandinavian journal of immunology: 1984; 19 193 198 (Pubitemid 14171511)
6. Allin K. H., Bojesen S. E., Nordestgaard B. G. Baseline C-reactive protein is associated with incident cancer and survival in patients with cancer. J Clin Oncol: 2009; 27 2217 2224
7. Heikkila K., Harris R., Lowe G. et al. Associations of circulating C-reactive protein and interleukin-6 with cancer risk: findings from two prospective cohorts and a meta-analysis. Cancer Causes Control: 2009; 20 15 26
8. Canna K., McArdle P. A., McMillan D. C. et al. The relationship between tumour T-lymphocyte infiltration, the systemic inflammatory response and survival in patients undergoing curative resection for colorectal cancer. British journal of cancer: 2005; 92 651 654 (Pubitemid 40460599)
9. McMillan D. C., Canna K., McArdle C. S. Systemic inflammatory response predicts survival following curative resection of colorectal cancer. The British journal of surgery: 2003; 90 215 219 (Pubitemid 36237897)
10. Jamieson N. B., Glen P., McMillan D. C. et al. Systemic inflammatory response predicts outcome in patients undergoing resection for ductal adenocarcinoma head of pancreas. British journal of cancer: 2005; 92 21 23 (Pubitemid 40188430)
11. Heys S. D., Ogston K. N., Simpson W. G. et al. Acute phase proteins in patients with large and locally advanced breast cancer treated with neo-adjuvant chemotherapy: response and survival. International journal of oncology: 1998; 13 589 594 (Pubitemid 28372686)
12. Guillem P., Triboulet J. P. Elevated serum levels of C-reactive protein are indicative of a poor prognosis in patients with esophageal cancer. Dis Esophagus: 2005; 18 146 150 (Pubitemid 41801107)
13. McArdle P. A., Mir K., Almushatat A. S. et al. Systemic inflammatory response, prostate-specific antigen and survival in patients with metastatic prostate cancer. Urologia internationalis: 2006; 77 127 129 (Pubitemid 44195771)
14. Van Hemelrijck M., Jungner I., Walldius G. et al. Risk of prostate cancer is not associated with levels of C-reactive protein and other commonly used markers of inflammation. International journal of cancer
15. Platz E. A., De Marzo A. M., Erlinger T. P. et al. No association between pre-diagnostic plasma C-reactive protein concentration and subsequent prostate cancer. The Prostate: 2004; 59 393 400 (Pubitemid 38661806)
16. Il'yasova D., Colbert L. H., Harris T. B. et al. Circulating levels of inflammatory markers and cancer risk in the health aging and body composition cohort. Cancer Epidemiol Biomarkers Prev: 2005; 14 2413 2418 (Pubitemid 41437845)
17. Siemes C., Visser L. E., Coebergh J. W. et al. C-reactive protein levels, variation in the C-reactive protein gene, and cancer risk: the Rotterdam Study. J Clin Oncol: 2006; 24 5216 5222 (Pubitemid 46631365)
18. Twillie D. A., Eisenberger M. A., Carducci M. A. et al. Interleukin-6: a candidate mediator of human prostate cancer morbidity. Urology: 1995; 45 542 549
19. Adler H. L., McCurdy M. A., Kattan M. W. et al. Elevated levels of circulating interleukin-6 and transforming growth factor-beta1 in patients with metastatic prostatic carcinoma. The Journal of urology: 1999; 161 182 187 (Pubitemid 29422316)
20. Lehrer S., Diamond E. J., Mamkine B. et al. C-reactive protein is significantly associated with prostate-specific antigen and metastatic disease in prostate cancer. BJU international: 2005; 95 961 962 (Pubitemid 40655687)
21. Drachenberg D. E., Elgamal A. A., Rowbotham R. et al. Circulating levels of interleukin-6 in patients with hormone refractory prostate cancer. The Prostate: 1999; 41 127 133 (Pubitemid 29446967)
22. Trichopoulos D., Psaltopoulou T., Orfanos P. et al. Plasma C-reactive protein and risk of cancer: a prospective study from Greece. Cancer Epidemiol Biomarkers Prev: 2006; 15 381 384 (Pubitemid 43348407)
23. Gakis G., Todenhofer T., Renninger M. et al. Development of a new outcome prediction model in carcinoma invading the bladder based on preoperative serum C-reactive protein and standard pathological risk factors: the TNR-C score. BJU international 108 1800 1805
24. Yoshida S., Saito K., Koga F. et al. C-reactive protein level predicts prognosis in patients with muscle-invasive bladder cancer treated with chemoradiotherapy. BJU international: 2008; 101 978 981 (Pubitemid 351422558)
25. Johnson T. V., Abbasi A., Owen-Smith A. et al. Absolute preoperative C-reactive protein predicts metastasis and mortality in the first year following potentially curative nephrectomy for clear cell renal cell carcinoma. The Journal of urology 183 480 485
26. Grossman H. B., Natale R. B., Tangen C. M. et al. Neoadjuvant chemotherapy plus cystectomy compared with cystectomy alone for locally advanced bladder cancer. The New England journal of medicine: 2003; 349 859 866 (Pubitemid 37025405)
27. Cindolo L., Patard J. J., Chiodini P. et al. Comparison of predictive accuracy of four prognostic models for nonmetastatic renal cell carcinoma after nephrectomy: a multicenter European study. Cancer: 2005; 104 1362 1371 (Pubitemid 41356151)
28. Karakiewicz P. I., Suardi N., Capitanio U. et al. A preoperative prognostic model for patients treated with nephrectomy for renal cell carcinoma. European urology: 2009; 55 287 295
29. Galfano A., Novara G., Iafrate M. et al. Mathematical models for prognostic prediction in patients with renal cell carcinoma. Urologia internationalis: 2008; 80 113 123 (Pubitemid 351440502)
30. Tan M. H., Li H., Choong C. V. et al. The Karakiewicz nomogram is the most useful clinical predictor for survival outcomes in patients with localized renal cell carcinoma. Cancer 117 5314 5324
31. George S., Bukowski R. M. Biomarkers in clear cell renal cell carcinoma. Expert review of anticancer therapy: 2007; 7 1737 1747 (Pubitemid 350303004)
32. Crispen P. L., Boorjian S. A., Lohse C. M. et al. Predicting disease progression after nephrectomy for localized renal cell carcinoma: the utility of prognostic models and molecular biomarkers. Cancer: 2008; 113 450 460
33. Jagdev S. P., Gregory W., Vasudev N. S. et al. Improving the accuracy of pre-operative survival prediction in renal cell carcinoma with C-reactive protein. British journal of cancer 103 1649 1656
34. Bui M. H., Seligson D., Han K. R. et al. Carbonic anhydrase IX is an independent predictor of survival in advanced renal clear cell carcinoma: implications for prognosis and therapy. Clin Cancer Res: 2003; 9 802 811 (Pubitemid 36182618)
35. Ito K., Asano T., Yoshii H. et al. Impact of thrombocytosis and C-reactive protein elevation on the prognosis for patients with renal cell carcinoma. Int J Urol: 2006; 13 1365 1370 (Pubitemid 44657040)
36. Lamb G. W., McMillan D. C., Ramsey S. et al. The relationship between the preoperative systemic inflammatory response and cancer-specific survival in patients undergoing potentially curative resection for renal clear cell cancer. British journal of cancer: 2006; 94 781 784
37. Casamassima A., Picciariello M., Quaranta M. et al. C-reactive protein: a biomarker of survival in patients with metastatic renal cell carcinoma treated with subcutaneous interleukin-2 based immunotherapy. The Journal of urology: 2005; 173 52 55 (Pubitemid 39627670)
38. Fujikawa K., Matsui Y., Oka H. et al. Serum C-reactive protein level and the impact of cytoreductive surgery in patients with metastatic renal cell carcinoma. The Journal of urology: 1999; 162 1934 1937
39. Komai Y., Saito K., Sakai K. et al. Increased preoperative serum C-reactive protein level predicts a poor prognosis in patients with localized renal cell carcinoma. BJU international: 2007; 99 77 80 (Pubitemid 44915624)
40. Bui M. H., Visapaa H., Seligson D. et al. Prognostic value of carbonic anhydrase IX and KI67 as predictors of survival for renal clear cell carcinoma. The Journal of urology: 2004; 171 2461 2466 (Pubitemid 38625515)
41. Lee S. E., Byun S. S., Han J. H. et al. Prognostic significance of common preoperative laboratory variables in clear cell renal cell carcinoma. BJU international: 2006; 98 1228 1232 (Pubitemid 44721231)
42. Steffens S., Köhler A., Rudolph R. et al. Validation of CRP as prognostic marker for renal cell carcinoma in a large series of patients. BMC Cancer: 2012; 12 399
43. Stein B., Schrader A. J., Wegener G. et al. Preoperative serum C-reactive protein: a prognostic marker in patients with upper urinary tract urothelial carcinoma. BMC Cancer: 2013; 13 101
44. Steffens S., Al Ghazal A., Steinestel J. et al. High CRP values predict poor survival in patients with penile cancer. BMC Cancer: 2013; 13 223